Overview
Sponsor-declared trial summary
Obesity, Overweight
Demonstrate whether QW tirzepatide is superior to placebo in reducing morbidity and mortality.
Key facts
- Sponsor
- Eli Lilly & Co.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Trial duration
- 23 Jan 2023 → ongoing
- Decision date (initial)
- 2023-01-23
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
External identifiers
- EU CT number
- 2022-501744-15-00
- ClinicalTrials.gov
- NCT04657003
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Efficacy, Safety, Therapy
Demonstrate whether QW tirzepatide is superior to placebo in reducing morbidity and mortality.
Conditions and MedDRA coding
Obesity, Overweight
Study design 1 period
| # | Title | Allocation | Blinding | Roles blinded | Arms |
|---|---|---|---|---|---|
| 1 | Parallel Assignment N/A
|
Randomised Controlled | Double | [{"id":183480,"code":2,"name":"Investigator"},{"id":183479,"code":1,"name":"Subject"}] | Experimental: Tirzepatide: Participants will receive escalated doses of tirzepatide subcutaneously (SC) up to a maximum tolerated dose Placebo Comparator: Participants will receive tirzepatide matched placebo |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency
- Plan to share IPD
- Yes
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 4
- Be overweight or have obesity
- Are over age 40 and have cardiovascular disease at least 3 months before study start
- Women at least 55 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease.
- Men at least 50 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease.
Exclusion criteria 2
- Have type 1 diabetes or type 2 diabetes at the beginning of the study
- Have any of the cardiovascular conditions such as: heart attack, stroke, procedure to treat coronary artery disease, or heart failure requiring IV medication or left ventricular assist device within 3 months before the start of the study
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 6
PRD11922457 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INJECTION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD11922453 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INJECTION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD11922458 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INJECTION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD11922456 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INJECTION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD11922454 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INJECTION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
PRD11922455 · Product
- Active substance
- Tirzepatide
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED PEN
- Route of administration
- SOLUTION FOR INFUSION
- Max daily dose
- 2.14 mg milligram(s)
- Max total dose
- 4.86 g gram(s)
- Max treatment duration
- 324 Week(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
Placebo to match ly3298176 injection
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Eli Lilly & Co.
- Sponsor organisation
- Eli Lilly & Co.
- Address
- 1 Lilly Corporate Center
- City
- Indianapolis
- Postcode
- 46285-0001
- Country
- United States
Scientific contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Public contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Third parties 13
| Organisation | City, country | Duties |
|---|---|---|
| Pharmaserve Lilly S.A.C.I. ORG-100005347
|
Kifissia, Greece | On site monitoring, Code 12, Other, Code 2, Code 5 |
| Iqvia Inc. ORG-100010622
|
Durham, United States | On site monitoring |
| Q Squared Solutions LLC ORG-100043195
|
Durham, United States | Laboratory analysis |
| Vita Verum Medical Bt. ORG-100039249
|
Szekesfehervar, Hungary | Other |
| Greenphire LLC ORG-100041621
|
King Of Prussia, United States | Other |
| Q Squared Solutions Limited ORG-100042527
|
Reading, United Kingdom | Laboratory analysis |
| Q2 Solutions LLC ORG-100017000
|
Ithaca, United States | Laboratory analysis |
| Revise LLC ORL-000008140
|
Austin, Texas, United States | Other |
| Yprime LLC ORG-100042888
|
Malvern, United States | E-data capture |
| Bioagilytix Labs LLC ORG-100013030
|
Durham, United States | Laboratory analysis |
| Trendyminds LLC ORG-100045580
|
Indianapolis, United States | Other |
| Praxis Communications LLC ORG-100045170
|
Buffalo, United States | Other |
| Cleveland Clinic ORG-100028017
|
Cleveland, United States | Code 11, Other |
Locations
13 EU/EEA countries · 210 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruitment ended | 100 | 7 |
| Belgium | Ongoing, recruitment ended | 90 | 9 |
| Czechia | Ongoing, recruitment ended | 350 | 14 |
| France | Ongoing, recruitment ended | 116 | 13 |
| Germany | Ongoing, recruitment ended | 626 | 22 |
| Greece | Ongoing, recruitment ended | 300 | 14 |
| Hungary | Ongoing, recruitment ended | 350 | 18 |
| Italy | Ongoing, recruitment ended | 200 | 16 |
| Netherlands | Ongoing, recruitment ended | 110 | 12 |
| Poland | Ongoing, recruitment ended | 470 | 23 |
| Romania | Ongoing, recruitment ended | 375 | 25 |
| Slovakia | Ongoing, recruitment ended | 105 | 7 |
| Spain | Ongoing, recruitment ended | 490 | 30 |
| Rest of world
Japan, China, Mexico, Argentina, Turkey, United States, Taiwan, Israel, Canada, Australia, Brazil, United Kingdom, India, Korea, Republic of
|
— | 11,318 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2023-02-16 | 2023-03-06 | 2023-12-15 | ||
| Belgium | 2023-02-07 | 2023-02-20 | 2023-12-15 | ||
| Czechia | 2023-02-03 | 2023-02-13 | 2023-12-15 | ||
| France | 2023-01-24 | 2023-01-27 | 2023-12-15 | ||
| Germany | 2023-01-24 | 2023-01-26 | 2023-12-15 | ||
| Greece | 2023-02-07 | 2023-02-09 | 2023-12-15 | ||
| Hungary | 2023-01-23 | 2023-01-27 | 2023-12-15 | ||
| Italy | 2023-02-13 | 2023-03-06 | 2023-12-15 | ||
| Netherlands | 2023-01-31 | 2023-02-20 | 2023-12-15 | ||
| Poland | 2023-02-01 | 2023-02-06 | 2023-12-15 | ||
| Romania | 2023-02-16 | 2023-02-22 | 2023-12-15 | ||
| Slovakia | 2023-02-08 | 2023-02-13 | 2023-12-15 | ||
| Spain | 2023-01-25 | 2023-01-30 | 2023-12-15 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 469 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_ Protocol 2022-501744-15-00_Redacted | d |
| Protocol (for publication) | D1_Protocol_2022-501744-15-00_GR_Redacted | d |
| Protocol (for publication) | GPIJ_Harmonized Clinical Protocol-Greece_redacted | 1 |
| Protocol (for publication) | Patient Facing Documents_For Publication_for MS NL only | 1 |
| Recruitment arrangements (for publication) | 2_Lilly_SURMOUNT-MMO_Patient Invite-to-Trial Letter_GR | 1 |
| Recruitment arrangements (for publication) | 2_Lilly_SURMOUNT-MMO_Recruitment Brochure_GR | 1 |
| Recruitment arrangements (for publication) | 2_Lilly_SURMOUNT-MMO_Recruitment Poster_GR | 1 |
| Recruitment arrangements (for publication) | GPIJ_CZ_List of planned sites_05Aug2022_Redacted | 1 |
| Recruitment arrangements (for publication) | GPIJ_CZ_Recruitment and ICF procedure_05Aug2022 | 1 |
| Recruitment arrangements (for publication) | GPIJ_Recruitment and Informed consent procedure_GREECE_Redacted | 1 |
| Recruitment arrangements (for publication) | GPIJ_Recruitment Arrangements_04Aug2022_Redacted | 1 |
| Recruitment arrangements (for publication) | GPIJ_Recruitment Arrangements_Redacted | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements procedure_french_v2.0_TC | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_redacted | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Procedure | 4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Procedure_TC | 4.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_ES_Patient Invite-to-Trial Letter | 1.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_ES_Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_ES_Recruitment Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_GI Side Effect Card_M_DE | 1.0 |
| Recruitment arrangements (for publication) | K2_List of participating sites_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Family Engagement Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Family Engagement Brochure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material GI Side Effect Card | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material GI Side Effect Card | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Making Healthy Food Choices | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Making Healthy Food Choices | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Recruitment Brochure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Recruitment Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Recruitment Poster | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Staying Fit Through An Active Lifestyle | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Staying Fit Through An Active Lifestyle | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Thank You Card | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Thank You Card | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Clinical Trial Ancillary Supply List | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Dr-to-Patient Invitation Letter | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Dr-to-Patient Invitation Letter | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Dr-to-Patient Invitation Letter_DU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Dr-to-Patient Invitation Letter_FR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Dr-to-Patient Invitation Letter_NL_v1_16Mar2023 | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Dr-to-Patient Invitation Letter_TC | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Family Engagement Brochure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Family Engagement Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Family Engagement Brochure_DU | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Family Engagement Brochure_FR | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Family Engagement Brochure_M_DE | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Family Engagement Brochure_NL_v1_01Feb2023 | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_GI Side Effect Card | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_GI Side Effect Card | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_GI Side Effect Card_DU | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_GI Side Effect Card_FR | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_GP to Patient letter GPRI_NL_v1_01Feb2023_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_GP to Patient letter GPRI_TC_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Making Healthy Food Choices_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Making Healthy Food Choices_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Invite-to-Trial Letter | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Invite-to-Trial Letter_DE | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Recruitment Brochure_DU | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Recruitment Brochure_FR | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure_M_DE | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure_NL_v1_01Feb2023 | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Brochure_TC | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Recruitment Poster_DU | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Recruitment Poster_FR | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster_M_DE | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster_NL_v1_01Feb2023 | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Poster_TC | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_Family Engagement Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_GI Side Effect Card | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_Making Healthy Food Choices | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_Recruitment Brochure | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_Recruitment Poster | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_Staying Fit Through An Active Lifestyle | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_SK_v1_Thank You Card | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Staying Fit Through An Active Lifestyle_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Staying Fit Through An Active Lifestyle_BEFR | 1.0 |
| Recruitment arrangements (for publication) | List of planned Sites and Subject_ITA redacted | 3.0 |
| Recruitment arrangements (for publication) | List of planned sites_CZ_Redacted | 2 |
| Recruitment arrangements (for publication) | List of Planned Sites_redacted | 2.0 |
| Recruitment arrangements (for publication) | Recruitment and Informed consent procedure | 1 |
| Recruitment arrangements (for publication) | Recruitment and Informed consent procedure | 2.0 |
| Recruitment arrangements (for publication) | Recruitment Arrangements__ENG_Redacted | 1 |
| Recruitment arrangements (for publication) | Recruitment Arrangements_ENG_Redacted | 1 |
| Recruitment arrangements (for publication) | Recruitment Arrangements_ENG_Redacted | 1 |
| Recruitment arrangements (for publication) | Recruitment Arrangements_ENG_Redacted | 1 |
| Recruitment arrangements (for publication) | Recruitment Arrangements_Redacted | 2.0 |
| Recruitment arrangements (for publication) | Recruitment Arrangements_Redacted | 1 |
| Recruitment arrangements (for publication) | Recruitment arrangements-RO GPIJ | 1 |
| Subject information and informed consent form (for publication) | 1 Patient Facing Documents_For Publication_v1_26Aug2022_ENG | 1 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ__Redacted | 1.0 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ_Redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ_Redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ_Redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ_Redacted | 1 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List for I8F-MC-GPIJ_v2_05Aug2022_Redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List__Redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List_redacted | 2 |
| Subject information and informed consent form (for publication) | Clinical Trial Ancillary Supply List_v2_05Aug2022_Redacted | 2 |
| Subject information and informed consent form (for publication) | ConneX France Travel Contact Card | 3.0 |
| Subject information and informed consent form (for publication) | ConneX France Travel Ref Guide | 3.0 |
| Subject information and informed consent form (for publication) | Consent Procedure | 2.0 |
| Subject information and informed consent form (for publication) | Country Subject Directions for Use_DFU of IP | 1 |
| Subject information and informed consent form (for publication) | Czech_Greenphire ClinCard Msg Templates_ROW v6_0 Feb 2018_CZ | 6 |
| Subject information and informed consent form (for publication) | Czech_Greenphire ClinCard Travel Ref Guide for Subjects_v3_CZ | 3 |
| Subject information and informed consent form (for publication) | Czech_Greenphire Travel Contact Card_2_CZ_July2016 | 2 |
| Subject information and informed consent form (for publication) | Czech_Greenphire_ClinCard_Card_Carrier_V1__CZ | 1 |
| Subject information and informed consent form (for publication) | Czech_Greenphire_ClinCard_Cardholder_FAQ_EU_V3_CZ | 3 |
| Subject information and informed consent form (for publication) | Czech_Greenphire_Fee_Schedule_V4_CZ | 4 |
| Subject information and informed consent form (for publication) | Czech_Republic_-_EC_packet_w_Data_Laws_as_applied_to_GP_v6_ENG | 6 |
| Subject information and informed consent form (for publication) | D4_Patient Facing Documents_For Publication_ENG | 1.0 |
| Subject information and informed consent form (for publication) | EC packet with Data Privacy as applied to GP | 7 |
| Subject information and informed consent form (for publication) | EC_packet_w_Data_Privacy_as_applied_to_GP | 7.0 |
| Subject information and informed consent form (for publication) | General ConneX EC packet with Data Privacy as applied to GP | 2 |
| Subject information and informed consent form (for publication) | General_ConneX_EC_Data_Privacy | 1.0 |
| Subject information and informed consent form (for publication) | General_ConneX_EC_packet_w_Data_Privacy_as_applied_to_GP | 2 |
| Subject information and informed consent form (for publication) | General_ConneX_EC_packet_w_Data_Privacy_as_applied_to_GP | 2 |
| Subject information and informed consent form (for publication) | General_ConneX_EC_packet_w_Data_Privacy_as_applied_to_GP_0 | 1 |
| Subject information and informed consent form (for publication) | General_ConneX_EC_packet_w_Data_Privacy_as_applied_to_GP_v2_CZ | 2 |
| Subject information and informed consent form (for publication) | Genetic Addendum Informed Consent Form | 1 |
| Subject information and informed consent form (for publication) | Genetic addendum Informed Consent Form_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | Genetic addendum Informed Consent Form_Track changed_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | German_Germany _ ConneX Germany Travel Contact Card | 1 |
| Subject information and informed consent form (for publication) | German_Germany _ ConneX Germany Travel Ref Guide for Subjects | 1 |
| Subject information and informed consent form (for publication) | German_Germany _ Greenphire ClinCard Msg Templates _ ROW | 1 |
| Subject information and informed consent form (for publication) | German_Germany _ Greenphire_ClinCard_Card_Carrier | 1 |
| Subject information and informed consent form (for publication) | German_Germany _ Greenphire_ClinCard_Cardholder_FAQ_EU | 1 |
| Subject information and informed consent form (for publication) | German_Germany _ Greenphire_Fee_Schedule | 1 |
| Subject information and informed consent form (for publication) | Germany_EC_packet_Data_Privacy_as_applied_to_GP | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Clinical Trial Ancillary Supply List_Redacted | 2 |
| Subject information and informed consent form (for publication) | GPIJ_Country Reimbursement ICF Addendum_DE_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | GPIJ_ICF Pregnant Partner_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | GPIJ_ICF Pregnant Partner_v1.1_1Dec2022_TC_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | GPIJ_ICF_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | GPIJ_List of ssICF contact details__DE_Redacted | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Main Country Informed Consent Form_DE_Final_Redacted | 4.1 |
| Subject information and informed consent form (for publication) | GPIJ_Main ICF_v1.2_1Dec2022_TC_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Ebenbichler__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Hanusch__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_KautzkyWiller__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Ludvik__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Sourij__0__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Stulnig__0__DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_Patient card_Vonbank_DE | 1 |
| Subject information and informed consent form (for publication) | GPIJ_SK_Main ICFtracked changes | 1.1 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Card Carrier_redacted | 1 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Cardholder FAQ EU | 3 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard EU Card Design | 1.0 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Msg Templates - ROW | 5.0 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Msg Templates - ROW | 6 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Travel Ref Guide for Subjects | 3.0 |
| Subject information and informed consent form (for publication) | Greenphire ClinCard Travel Ref Guide for Subjects | 3 |
| Subject information and informed consent form (for publication) | Greenphire Fee Schedule_redacted | 4 |
| Subject information and informed consent form (for publication) | Greenphire Travel Contact Card | 2 |
| Subject information and informed consent form (for publication) | Greenphire_ClinCard_Card_Carrier | 1.0 |
| Subject information and informed consent form (for publication) | Greenphire_ClinCard_Cardholder_FAQ_EU | 1.0 |
| Subject information and informed consent form (for publication) | Greenphire_Fee_Schedule | 1.0 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_EQ-5D-5L_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Foglio Informativo e Consenso Informato_Italia _Clean_redacted | 3.0 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Foglio Informativo e Consenso Informato_Italia _Clean_Redacted | 3 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Foglio Informativo e Consenso Informato_Italia _TC_Redacted | 3 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Foglio Informativo e Consenso Informato_Italia_TC_redacted | 3.0 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_GP Letter_ITA_Clean | 4.0 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_GP Letter_ITA_TC | 4.0 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Greenphire ICF_RO_clean | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_HOOS_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_KOOS_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Main ICF_PL_Redacted | 4 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Main ICF_PL_TC_redacted | 4 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Main ICF_RO_TC | 6 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_OSFT_ScreenReport_v2_Trans_eCOA_YPrime | 2 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_PGIS_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_PNRS Hip_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_PNRS Knee_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_SF-36_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_SK_ICF DPA_clean | 1.1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_SK_ICF DPA_tracked changes | 1.1 |
| Subject information and informed consent form (for publication) | I8F-MC-GPIJ_Tablet Training Questionnaire_ScreenReport_v1_Trans_eCOA_YPrime | 1 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_Clean_CZ_Redacted | 3 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_CZ_final_Redacted | 4.0 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_highlighted_Redacted_CZ | 3 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_TC_CZ_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_tc_Redacted_CZ | 3 |
| Subject information and informed consent form (for publication) | ICF Addednum_Reimbursement_V2_CZ_final_Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF Data Privacy Addendum_CZ_clean | 2 |
| Subject information and informed consent form (for publication) | ICF Data Privacy Addendum_CZ_highlighted | 2 |
| Subject information and informed consent form (for publication) | ICF Data Privacy Addendum_CZ_tc | 2 |
| Subject information and informed consent form (for publication) | ICF Data Privacy Addendum_Final | 1.0 |
| Subject information and informed consent form (for publication) | ICF DU Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF DU TC Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF ENG Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF ENG TC Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF FR Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF FR TC Redacted | 2 |
| Subject information and informed consent form (for publication) | ICF Sponsor Statement_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | ICF_I8F-MC-GPIJ_MAIN | 3 |
| Subject information and informed consent form (for publication) | ICF_I8F-MC-GPIJ_MAIN_track changes | 2 |
| Subject information and informed consent form (for publication) | ICF_Template_Germany_Patient Reimbursement Program_GER_Redacted | 1 |
| Subject information and informed consent form (for publication) | Idoneidad del investigador_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Appreciation items | 1 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Appreciation items | 1.0 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Emergency Card | 1.0 |
| Subject information and informed consent form (for publication) | K2_Recruitment Material_Emergency Card_DU | 1 |
| Subject information and informed consent form (for publication) | K2_Recruitment Material_Emergency Card_FR | 1 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Making Healthy Food Choices | 2.1 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Making Healthy Food Choices_TC | 2.1 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Staying Fit Through An Active Lifestyle | 1.0 |
| Subject information and informed consent form (for publication) | K2_Recruitment material_Thank You Card | 1.0 |
| Subject information and informed consent form (for publication) | K2_Recruitment Material_Thank You Card_DU | 1 |
| Subject information and informed consent form (for publication) | K2_Recruitment Material_Thank You Card_FR | 1 |
| Subject information and informed consent form (for publication) | L1_Country Reimbursement and Reminder Addendum ICF_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF Amendment Summary | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF Amendment Summary | 8 |
| Subject information and informed consent form (for publication) | L1_ICF Netherlands_NL_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF_Pregnant Partner_GR | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_SoC | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_SoC 2_PL | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF_SoC_Main_GR_ | 1 |
| Subject information and informed consent form (for publication) | L1_Main ICF Summary of Changes | 1 |
| Subject information and informed consent form (for publication) | L1_Main ICF_Optional Activity_GR_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Main ICF_Summary of changes_GR | 1 |
| Subject information and informed consent form (for publication) | L1_Optional Activity Consent_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Reimbursement ICF Addendum_Redacted | 3 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF addendum continuous access_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF addendum continuous access_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF addendum_Contact by localization vendor_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF adults_Italian to Spanish Arg_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_TC_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Activity Consent_BEDU_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Activity Consent_BEFR_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Optional Activity Consent_ENG_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Summary of Changes_DE | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ ICF Summary of Changes | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum ICF Optional Activity_Italian to Spanish Arg_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum ICF Optional Activity_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Additional Optional Activity Consent_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_GPIJ_SK_Main ICF_tracked changes_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ICF Summary of Changes_BEDU | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_ICF Summary of Changes_BEFR | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Clean_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_TC_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main SoC-2 | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_SoC | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_SoC_10Dec2025 | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_SoC_18Jun2024_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional activity consent_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity Consent_SK_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional activity ICF_CZ_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity_06May2025_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PL_Optional Activity ICF_GPIJ_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant parent | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_SoC | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_SoC_Italian to Argentinian Spanish | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes | 2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of Changes | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes ICF_Clean | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes ICF_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes Main ICF | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of changes Main ICF_ | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of Changes_Clean_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of Changes_CZ | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of Changes_DE | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Summary of Changes_Italian to Spanish Arg | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_TC_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material Emergency Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material Family Engagement Brochure | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material GI Side Effect Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material Making Healthy Food Choices | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material Staying Fit Through An Active Lifestyle | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material Thank You Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_Family Engagement Brochure | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_GI Side Effect Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_Making Healthy Food Choices | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_Patient Invite-to-Trial Letter | 1 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_Staying Fit Through An Active Lifestyle | 1.0 |
| Subject information and informed consent form (for publication) | L2_ Other subject information material_Thank You Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Appreciation Items | 1 |
| Subject information and informed consent form (for publication) | L2_appreciation items with Price_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Appreciation Items_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Clinical Trial Ancillary Supply List_Dutch_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Clinical Trial Ancillary Supply List_ENG_Redacted | 2.0 |
| Subject information and informed consent form (for publication) | L2_Emergency Card _GR | 1 |
| Subject information and informed consent form (for publication) | L2_Family Engagement Brochure_GR | 1 |
| Subject information and informed consent form (for publication) | L2_GI Side Effect Card_GR | 1 |
| Subject information and informed consent form (for publication) | L2_GPIJ-DE-DE-PATIENT-FLYER_metadata | 1 |
| Subject information and informed consent form (for publication) | L2_Instructions for Use_CZ | 1 |
| Subject information and informed consent form (for publication) | L2_Making Healthy Food Choices_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material communication ICF Summary of Changes | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material communication ICF Summary of Changes | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material Emergency Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material Emergency Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ eCOA Translation Certificate Spanish ARG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Eating-Well | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Eating-Well-DG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Healthy-Connections | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Healthy-Connections-DG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Managing-Stress | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Managing-Stress-DG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Moving-More | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-of-Moving-More-DG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-to-Better-Sleep | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_7-Days-to-Better-Sleep-DG | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Emergency Card | 2.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Emergency Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_GI Side Effect Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_HOOS_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_HU_site_56474_Home_Dosing_Diary | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Informed Consent Form ITIT V3 13 Mar 2023_es-ARG_TCERT | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Insurance Conditions | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_KOOS_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Making Healthy Food Choices | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_PGIS_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_PNRS Hip_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_PNRS Knee_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_ScreenReport_eCOA_YPrime_Spanish-AR-07Sep2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_SF-36_ScreenReport_Trans_eCOA_YPrime_Spanish-AR_06Oct2022 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_SoC_Summary ICF_Italia_es-ARG_TCERT | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Staying Fit Through An Active Lifestyle | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Summary ICF_Italia_es-ARG_TCERT | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Tablet Questionnaire_ScreenReport_v1_eCOA_Spanish-AR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Thank You Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Translated eCOA Screenshots ARSP | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Translated eCOA Screenshots ARSP 04 Oct 2021 | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Translation Certificate Spanish ARG | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Welcome-Guide | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Welcome-Guide-DG | 1 |
| Subject information and informed consent form (for publication) | L2_patient cards | 1.0 |
| Subject information and informed consent form (for publication) | L2_Patient Flyer | 1 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Appreciation items | 1 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Emergency Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Emergency Card_M_DE | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Making Healthy Food Choices | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Making Healthy Food Choices | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Staying Fit Through An Active Lifestyle | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Staying Fit Through An Active Lifestyle | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Thank You Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Recruitment material_Thank You Card_M_DE | 1.0 |
| Subject information and informed consent form (for publication) | L2_Staying Fit Through An Active Lifestyle_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Support_by_Sidekick_Abbreviated_Screenshots | 1 |
| Subject information and informed consent form (for publication) | L2_Support_by_Sidekick_Abbreviated_Screenshots | 1 |
| Subject information and informed consent form (for publication) | L2_Support_by_Sidekick_ERB_Overview_Letter | 1 |
| Subject information and informed consent form (for publication) | L2_Support_by_Sidekick_ERB_Overview_Letter | 1 |
| Subject information and informed consent form (for publication) | L2_Thank You Card_GR | 1 |
| Subject information and informed consent form (for publication) | L3_ Appreciation Items | 3 |
| Subject information and informed consent form (for publication) | L3_ Appreciation Items | 3.0 |
| Subject information and informed consent form (for publication) | L3_Appreciation items | 3 |
| Subject information and informed consent form (for publication) | L3_Appreciation items list | 1 |
| Subject information and informed consent form (for publication) | L3_Appreciation items list | 1 |
| Subject information and informed consent form (for publication) | L4_List of Submitted Documents_SM-1_2022-501744-15 | 1 |
| Subject information and informed consent form (for publication) | Lilly_Kostenubernahme_Hotel_Lilly Logo_Redacted | 1 |
| Subject information and informed consent form (for publication) | Lilly_Thank you card | 1.0 |
| Subject information and informed consent form (for publication) | List of submitted documents_Part II_2022-5017-44-15_HU | 1 |
| Subject information and informed consent form (for publication) | Main Country Informed Consent Form_Track changes_DE_Redacted | 4.1 |
| Subject information and informed consent form (for publication) | Main ICF_Clean_CZ | 3 |
| Subject information and informed consent form (for publication) | Main ICF_CZ_final | 2.0 |
| Subject information and informed consent form (for publication) | Main ICF_final_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | Main ICF_GER_Redacted | 4.0 |
| Subject information and informed consent form (for publication) | Main ICF_highlighted_CZ | 3 |
| Subject information and informed consent form (for publication) | Main ICF_TC_CZ | 2.0 |
| Subject information and informed consent form (for publication) | Main ICF_tc_CZ | 3 |
| Subject information and informed consent form (for publication) | Main Informed Consent Form_HU_Redacted | 2 |
| Subject information and informed consent form (for publication) | Main Informed Consent Form_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | Main Informed Consent Form_Track changed_HU_Redacted | 2 |
| Subject information and informed consent form (for publication) | Main Informed Consent Form_Track changed_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publicatio_v1_26Aug2022_ENG | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication | 1.0 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_ENG | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_ENG | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_ENG | 1.0 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_ENG | 1.0 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_ENG | 1 |
| Subject information and informed consent form (for publication) | Patient Facing Documents_For Publication_v1_26Aug2022_ENG | 1 |
| Subject information and informed consent form (for publication) | Patient ID Card_draft | 1 |
| Subject information and informed consent form (for publication) | Patient Information Card | 1.0 |
| Subject information and informed consent form (for publication) | Patient Information Card | 1 |
| Subject information and informed consent form (for publication) | Patient Information Card CZ | 1 |
| Subject information and informed consent form (for publication) | Patient Information Card_GR_01OCT2013 | 2 |
| Subject information and informed consent form (for publication) | Poland_-_EC_packet_w_Data_Privacy_as_applied_to_GP | 8 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire ClinCard Msg Templates - ROW | 6 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire ClinCard Travel Ref Guide for Subjects | 3 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire Travel Contact Card | 1 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire_ClinCard_Card_Carrier | 1 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire_ClinCard_Cardholder_FAQ_EU | 3 |
| Subject information and informed consent form (for publication) | Polish-Poland - Greenphire_Fee_Schedule | 4 |
| Subject information and informed consent form (for publication) | Pregnant Participant ICF_ENG | 1.0 |
| Subject information and informed consent form (for publication) | Pregnant Participant ICF_FR | 1.0 |
| Subject information and informed consent form (for publication) | Pregnant Participant ICF_NL | 1.0 |
| Subject information and informed consent form (for publication) | Pregnant Partner ICF__FR | 1.0 |
| Subject information and informed consent form (for publication) | Pregnant Partner ICF_ENG | 1.0 |
| Subject information and informed consent form (for publication) | Pregnant Partner ICF_NL | 1.0 |
| Subject information and informed consent form (for publication) | Reimbursement Form_DE__Redacted | 3 |
| Subject information and informed consent form (for publication) | Reimbursement Form_DE_TC_Redacted | 3 |
| Subject information and informed consent form (for publication) | Reimbursement ICF Addendum_Redacted | 1 |
| Subject information and informed consent form (for publication) | Romania - Greenphire ClinCard Msg Templates - ROW | 6 |
| Subject information and informed consent form (for publication) | Romania - Greenphire_ClinCard_Cardholder_FAQ_EU_ | 3 |
| Subject information and informed consent form (for publication) | Romania - Greenphire_Fee_Schedule_ | 4 |
| Subject information and informed consent form (for publication) | Romania_-_EC_packet_w_Data_Privacy_as_applied_to_GP | 6 |
| Subject information and informed consent form (for publication) | Romania- Greenphire ClinCard Travel Ref Guide for Subjects | 3 |
| Subject information and informed consent form (for publication) | Romania- Greenphire Travel Contact Card_ | 2 |
| Subject information and informed consent form (for publication) | Romania- Greenphire_ClinCard_Card_Carrier_ | 10 |
| Subject information and informed consent form (for publication) | Subject Thank You Card | 1 |
| Subject information and informed consent form (for publication) | Template _ Greenphire EU Generic ClinCard | 1 |
| Subject information and informed consent form (for publication) | Template - Greenphire EU Generic ClinCard | 3 |
| Subject information and informed consent form (for publication) | Template Greenphire EU Generic ClinCard | 3 |
| Subject information and informed consent form (for publication) | Template_Greenphire EU Generic ClinCard_ENG_10April 2019 | 1 |
| Subject information and informed consent form (for publication) | TIRZEPATIDE_CT_GPIJ_IFU Saved final version 06_30_22_1_elGR | 1 |
| Subject information and informed consent form (for publication) | TIRZEPATIDE-CT-GPIJ-IFU Saved- final version_PL | 1 |
| Summary of Product Characteristics (SmPC) (for publication) | SmPC Mounjaro | 1 |
| Synopsis of the protocol (for publication) | Clinical Protocol Synopsis_HU | 1 |
| Synopsis of the protocol (for publication) | D1_ Protocol synopsis_ES_2022-501744-15-00_TC | 2.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis EN 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ BEDE 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ BEDU 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ BEFR 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ MS 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ MS 2022-501744-15-00_TC | 3.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ MS 2022-501744-15-00_Unapplied | 3.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15_ENG_TC | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_GR | b |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_GR_track changes | b |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_RO_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_SK_Clean | 1.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_SK_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_SK_Tracked Changes | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2022-501744-15-00_SK_Unapplied | d |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2024-501744-15-00_GR_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_AT_2022-501744-15-00 | c |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_AT_2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_AT_2022-501744-15-00_TC | c |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_CZ_2022-501744-15-00 | b |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_CZ_2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_CZ_2022-501744-15-00_TC | b |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ES_2022-501744-15-00 | b |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ES_2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_FRA_2022-501744-15-00 | c |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_FRA_2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_FRA_2022-501744-15-00_TC | c |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_PL 2022-501744-15-00_Redacted | d |
| Synopsis of the protocol (for publication) | D1_Protocol_Synopsis_IT_2022-501744-15-00_redacted | d |
| Synopsis of the protocol (for publication) | GPIJ Justification for Placebo _Redacted | 1 |
| Synopsis of the protocol (for publication) | GPIJ Protocol Synopsis_BEFR_TC | b |
| Synopsis of the protocol (for publication) | GPIJ Protocol Synopsis_GER | 2.0 |
| Synopsis of the protocol (for publication) | GPIJ Protocol Synopsis_PL_TC | b |
| Synopsis of the protocol (for publication) | GPIJ Protocol_Synopsis_BEDU_TC | b |
| Synopsis of the protocol (for publication) | GPIJ_Protocol Synopsis_BEGER_TC | b |
| Synopsis of the protocol (for publication) | GPIJ_Protocol Synopsis_GER_TC | 2.0 |
| Synopsis of the protocol (for publication) | GPIJ_Protocol Synopsis_PL | b |
| Synopsis of the protocol (for publication) | Protocol synopsis _RO TC | b |
| Synopsis of the protocol (for publication) | Protocol Synopsis_BE DE | b |
| Synopsis of the protocol (for publication) | Protocol Synopsis_BE FR | b |
| Synopsis of the protocol (for publication) | Protocol synopsis_RO | b |
| Synopsis of the protocol (for publication) | Protocol_Synopsis_BE NL | b |
| Synopsis of the protocol (for publication) | Protocol_Synopsis_ITA | b |
| Synopsis of the protocol (for publication) | Protocol_Synopsis_ITA_TC | b |
Application history
24 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2022-09-27 | Germany | Acceptable 2022-12-22
|
2022-12-22 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2023-03-14 | Acceptable 2022-12-22
|
2023-03-14 | |
| 3 | SUBSTANTIAL MODIFICATION | SM-1 | 2023-04-28 | Germany | Acceptable 2023-06-26
|
2023-06-27 |
| 4 | SUBSTANTIAL MODIFICATION | SM-2 | 2023-11-23 | Acceptable | 2024-01-16 | |
| 5 | SUBSTANTIAL MODIFICATION | SM-3 | 2023-12-11 | Acceptable | 2024-02-12 | |
| 6 | SUBSTANTIAL MODIFICATION | SM-4 | 2023-12-11 | Acceptable | 2024-02-13 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-5 | 2023-12-15 | Acceptable | 2024-02-06 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-6 | 2024-01-29 | Germany | Acceptable | 2024-02-07 |
| 9 | SUBSTANTIAL MODIFICATION | SM-7 | 2024-07-08 | Germany | Acceptable 2024-09-19
|
2024-09-19 |
| 10 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2024-10-30 | Acceptable 2024-09-19
|
2024-10-30 | |
| 11 | SUBSTANTIAL MODIFICATION | SM-8 | 2024-11-14 | Acceptable | 2024-12-31 | |
| 12 | SUBSTANTIAL MODIFICATION | SM-9 | 2024-12-03 | Acceptable | 2025-01-24 | |
| 13 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2025-01-28 | 2025-01-28 | ||
| 14 | SUBSTANTIAL MODIFICATION | SM-10 | 2025-01-31 | Acceptable | 2025-02-17 | |
| 15 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2025-04-09 | Acceptable | 2025-04-09 | |
| 16 | SUBSTANTIAL MODIFICATION | SM-11 | 2025-04-10 | Germany | Acceptable | 2025-04-14 |
| 17 | NON SUBSTANTIAL MODIFICATION | NSM-5 | 2025-05-02 | Germany | Acceptable | 2025-05-02 |
| 18 | NON SUBSTANTIAL MODIFICATION | NSM-6 | 2025-05-09 | Acceptable | 2025-05-09 | |
| 19 | SUBSTANTIAL MODIFICATION | SM-12 | 2025-07-11 | Germany | Acceptable 2025-10-02
|
2025-10-02 |
| 20 | NON SUBSTANTIAL MODIFICATION | NSM-7 | 2025-10-23 | Acceptable 2025-10-02
|
2025-10-23 | |
| 21 | SUBSTANTIAL MODIFICATION | SM-14 | 2025-10-31 | Acceptable | 2025-12-10 | |
| 22 | SUBSTANTIAL MODIFICATION | SM-15 | 2025-11-12 | Germany | Acceptable | 2025-12-16 |
| 23 | SUBSTANTIAL MODIFICATION | SM-16 | 2026-01-13 | Germany | Acceptable 2026-04-01
|
2026-04-01 |
| 24 | NON SUBSTANTIAL MODIFICATION | NSM-8 | 2026-04-30 | Acceptable 2026-04-01
|
2026-04-30 |